Biocompatibility Hemocompatibility In-Vitro

C3a Complement Activation Assay (V0022)

Test Options/Variations

V0022-000

Hemocompatibility tests are conducted to evaluate the adverse effects of blood-contacting medical devices or bio-materials on blood or blood components. The effects evaluated include adverse reactions such as thrombosis, hemolysis, platelet, leukocyte, and complement activation, and/or other blood-associated adverse events

STANDARDS

ISO 10993-4

  • As of September 2016, FDA Guidance release recommends the use of the SC5b9 Complement Activation Assay
Related Tests
Contact Us
Contact Us
Contact Us